scholarly journals Functional outcomes and patient satisfaction following inpatient treatment for childhood‐onset schizophrenia spectrum disorders vs non‐psychotic disorders in children in the United Kingdom

2020 ◽  
Author(s):  
Hayley Galitzer ◽  
Nefeli Anagnostopoulou ◽  
Anca Alba ◽  
Jorge Gaete ◽  
Danai Dima ◽  
...  
Keyword(s):  
Patient Satisfaction ◽  
Functional Outcomes ◽  
Inpatient Treatment ◽  
Psychotic Disorders ◽  
Schizophrenia Spectrum Disorders ◽  
Childhood Onset ◽  
The United Kingdom ◽  
Schizophrenia Spectrum ◽  
Childhood Onset Schizophrenia ◽  
Spectrum Disorders

scholarly journals Pathways to functional outcomes in schizophrenia spectrum disorders: Meta-analysis of social cognitive and neurocognitive predictors

2019 ◽  
Vol 105 ◽  
pp. 212-219 ◽  
Author(s):  
Tate F. Halverson ◽  
Maku Orleans-Pobee ◽  
Carrington Merritt ◽  
Paschal Sheeran ◽  
Anne-Kathrin Fett ◽  
...  
Keyword(s):  
Functional Outcomes ◽  
Social Cognitive ◽  
Meta Analysis ◽  
Schizophrenia Spectrum Disorders ◽  
Schizophrenia Spectrum ◽  
Spectrum Disorders

scholarly journals T196. THERAPEUTIC MANAGEMENT IN MULTIPLE SCLEROSIS AND SCHIZOPHRENIA SPECTRUM DISORDERS DUAL DIAGNOSIS

2020 ◽  
Vol 46 (Supplement_1) ◽  
pp. S306-S306
Author(s):  
Octavian Vasiliu
Keyword(s):  
Multiple Sclerosis ◽  
Dual Diagnosis ◽  
Atypical Antipsychotics ◽  
Psychotic Disorders ◽  
Complement Factor ◽  
Schizophrenia Spectrum Disorders ◽  
Positive Effects ◽  
Schizophrenia Spectrum ◽  
Baseline Values ◽  
Spectrum Disorders

Abstract Background Multiple sclerosis has been suggested as a potential vulnerability factor for schizophrenia and other psychotic disorders, and there is a hypothesis about a common etiology in a subgroup of schizophrenia and multiple sclerosis [1]. Immune-related single-nucleotide polymorphisms have been associated with schizophrenia and genetic pleiotropy between schizophrenia and multiple sclerosis has been reported, but not between bipolar disorder and multiple sclerosis (at the level of major histocompatibility complex) [2]. As new data about the involvement of genetically-determined immune factors in the susceptibility to schizophrenia appear (e.g., variants of complement factor 4 possibly linked to synaptic pruning during brain development) [3] the interest for finding therapeutic targets within the immune system for psychotic disorders is also increasing. Methods Three patients diagnosed with both schizophrenia spectrum disorders (schizophrenia n=2, or schizoaffective disorder, depressive type n=1), female, mean age 43.7, with a history of psychotic disorder for at least one year, were monitored during 6 months using Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF), Clinical Global Impressions – Severity (CGI-S), Columbia-Suicide Scale for Schizophrenia (CSSRS), Calgary Depression Scale (CDS), Multiple Sclerosis Severity Scale (MSSS), and the Extrapyramidal Symptom Rating Scale (ESRS). None of these patients presented other organic or psychiatric co-morbidity, and they were on active treatment for their multiple sclerosis throughout the 6-month duration of psychiatric evaluation. All patients were initiated on a new antipsychotic, because of the lack of efficacy of the previous agents, or due to their lack of therapeutic adherence. A patient was initiated on olanzapine 15 mg/day, while the other two received risperidone 4 mg/day. The antipsychotic doses were flexible during the 6 months of the treatment, with olanzapine between 10 and 20 mg daily, and risperidone between 3–6 mg daily. The initial PANSS mean score was 92.2, with a GAF of 35.3 and a CGI-S of 5.1. Results All patients reached the week 24 visit of their evaluation, and the overall tolerablity of the antipsychotic treatment was good. All patients had lower PANSS scores at week 24 (the mean decrease was -25.6 points compared to baseline), higher GAF scores (+27.7 points), and lower CGI-S (-2.5 points). CSSRS did not change significantly during the 6 months, the score remained at minimum value, and the CDS scores also remained constantly under 3. ESRS recorded transient increments, but at week 12 they were not significantly increased reported at the baseline values, and no corrective medication was recommended throughout the 6 months for extrapyramidal symptoms. MSSS mean score did not change significantly at week 12 compared to its baseline values. Discussion Atypical antipsychotics are efficient and well tolerated in patients with schizophrenia and multiple sclerosis dual diagnosis. The positive effects of atypical antipsychotics maintained during the 6 months of monitoring and they had no significant impact over the multiple sclerosis symptoms. References

Parental Schizophrenia Spectrum Disorders in Childhood-Onset and Adult-Onset Schizophrenia

2003 ◽  
Vol 160 (3) ◽  
pp. 490-495 ◽  
Author(s):  
Rob Nicolson ◽  
Frances B. Brookner ◽  
Marge Lenane ◽  
Peter Gochman ◽  
Loring J. Ingraham ◽  
...  
Keyword(s):  
Adult Onset ◽  
Schizophrenia Spectrum Disorders ◽  
Childhood Onset ◽  
Schizophrenia Spectrum ◽  
Spectrum Disorders

scholarly journals Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort – CORRIGENDUM

2020 ◽  
pp. 1-1
Author(s):  
Rosa Ayesa-Arriola ◽  
Víctor Ortíz-García de la Foz ◽  
Obdulia Martínez-García ◽  
Esther Setién-Suero ◽  
María Luz Ramírez ◽  
...  
Keyword(s):  
Functional Outcomes ◽  
First Episode ◽  
Schizophrenia Spectrum Disorders ◽  
Follow Up Study ◽  
Schizophrenia Spectrum ◽  
Spectrum Disorders ◽  
First Episode Schizophrenia
Sign in / Sign up

Export Citation Format

Share Document